Maternal care for anti-D [Rh] antibodies, first trimester (fetus 2)
ICD-10 O36.0112 is a billable code used to indicate a diagnosis of maternal care for anti-d [rh] antibodies, first trimester (fetus 2).
O36.0112 refers to maternal care for a pregnancy complicated by the presence of anti-D (Rh) antibodies during the first trimester, specifically for the second fetus in a multiple gestation. This condition arises when an Rh-negative mother carries an Rh-positive fetus, leading to the potential for hemolytic disease of the newborn (HDN) if not properly managed. The presence of these antibodies can cause fetal complications such as intrauterine growth restriction (IUGR), fetal distress, and even fetal demise if the condition is severe and left untreated. Close monitoring through ultrasound and serological testing is essential to assess fetal well-being and growth. Maternal care may include Rh immunoglobulin administration to prevent sensitization, as well as regular follow-ups to monitor the fetus's health and development. The management of this condition requires a multidisciplinary approach, often involving obstetricians and maternal-fetal medicine specialists to ensure optimal outcomes for both mother and fetus.
Detailed records of maternal blood tests, ultrasound findings, and treatment plans are essential.
Management of Rh-negative mothers with Rh-positive fetuses, monitoring for signs of fetal distress or growth restriction.
Accurate coding requires understanding of the implications of Rh incompatibility and its management.
Comprehensive documentation of high-risk factors, including maternal history and fetal assessments.
Complex cases involving multiple gestations and the management of potential fetal complications.
High-risk pregnancies necessitate thorough documentation of interventions and outcomes.
Used for comprehensive obstetric care in patients with Rh incompatibility.
Complete records of all prenatal visits, including assessments and interventions.
Obstetricians must document the specifics of care related to Rh antibody management.
Accurate coding of O36.0112 is crucial for ensuring appropriate management of Rh incompatibility, which can lead to serious fetal complications if not monitored and treated properly. It also impacts billing and reimbursement for the care provided.
